Is Pfizer's 5.7% Dividend Yield Worth the Risk?
Pharmaceutical giant Pfizer ( PFE 0.38%) stands out in this context. The company currently offers a mouthwatering 5.7% ...
Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi
Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...
The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly
The drugmaker’s fastest-growing blockbuster could soon face competition from two biotech firms in the treatment of a ...
Pharmabiz1h
Pfizer’s Braftovi+Mektovi shows long-term clinically meaningful response in patients with BRAF V600E-mutant metastatic NSCLC
Pfizer’s Braftovi+Mektovi shows long-term clinically meaningful response in patients with BRAF V600E-mutant metastatic NSCLC: New York Monday, September 16, 2024, 10:00 Hrs [IST ...
STAT6d
How Pfizer ended up passing on my GLP-1 work back in the early ’90s
One of the biopharma industry’s marvels of the 2020s has been the enormous medical and financial success of the GLP-1 class ...
Pfizer Stock Vs. AbbVie
In comparison, at its current levels of around $195, AbbVie stock trades at 18x expected 2024 earnings of $10.88 per share. This compares with the 12x average P/E multiple for ABBV seen over the last ...
A mural honoring scientists hung in Pfizer’s NYC lobby for 60 years. Now it’s up for grabs
NEW YORK (AP) — A mural honoring ancient and modern figures in medicine that has hung in the lobby of Pfizer’s original New ...
Pfizer : Phase 2 Study Of Ponsegromab In Cancer Cachexia Meets Primary Endpoint
Pfizer Inc. (PFE) said Saturday that its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation ...
Pfizer Inc. (PFE): A Bull Case Theory
We came across a bullish thesis on Pfizer Inc. (PFE) on gurufocus by Akim Guerreiro. In this article we will summarize the ...